Press Releases

Aspen Neuroscience to Present at 2024 Raymond James Biotech Private Company Showcase July 18

by
Damien McDevitt

SAN DIEGO, July 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the 2024 Raymond James Biotech Private Company Showcase on Thursday, July 18 at 11 a.m. PT / 2 p.m. ET. About Aspen NeuroscienceAspen Neuroscience, Inc., headquartered in San Diego, is … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at Stifel 2024 Cell Therapy Forum July 9

by
Untitled design 15

SAN DIEGO, July 8, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum this Tuesday, July 9 at 10:35am PT (1:35pm ET). A live webcast of the fireside chat will be broadcast … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting

by
Untitled design 13

Presentations Cover Aspen’s Autologous iPSC-derived Approach for Neuron Replacement Therapy in Trial for Parkinson’s Disease SAN DIEGO and VANCOUVER, BC, May 30, 2024 /PRNewswire/ — Aspen Neuroscience will present this week to a global audience of clinicians, regulators, researchers, technologists and industry partners at the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, May … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

by
Lisa Johnson Pratt, MD

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company’s executive management team in a new role as Senior Vice President, Therapeutic Program Lead. An industry leader with more than 25 years of experience, Dr. Johnson-Pratt will … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

FDA Grants Fast Track Designation to ANPD001, Autologous Investigational Cell Therapy for the Treatment of Parkinson’s Disease

by
cellimage001

SAN DIEGO, Oct. 19, 2023 /PRNewswire/ — Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ANPD001 for the treatment of Parkinson’s disease (PD) to improve motor function. ANPD001, is a personalized (autologous) cell therapy under investigation to treat PD by replacing lost dopamine neurons. The purpose of Fast … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona

by
wpc2023 logo color scaled

SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). “Preclinical Safety and Efficacy of Dopamine … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions

by
Andres ISSCR

SAN DIEGO, June 14, 2023 /PRNewswire/ — Today Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present “Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics,” during the Focus Sessions taking place during this week’s 2023 International Society for Stem Cell Research (ISSCR) Annual Meeting in Boston, Mass. His presentation will cover experiences … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson’s Disease

by
Human head with puzzle pieces

SAN DIEGO, Calif., April 12, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies, including the first autologous neuron replacement for Parkinson’s disease (PD), announced that this month it will launch the first patient screening study of its kind, working with multiple clinical screening sites in the … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Scientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officer

by
Xiaokui Zhang, Phd

SAN DIEGO, Calif., November 18, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Xiaokui Zhang, Ph.D., has joined the company as Chief Scientific Officer and as a member of the company’s executive team. With 20 years of progressive biopharmaceutical industry … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer

by
Kameel D. Farag

SAN DIEGO, Calif., Nov. 9, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kameel Farag has joined the company as Chief Financial Officer and as a member of the company’s executive team

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved